Methods and compositions for inhibiting the growth of hematopoietic malignant cells

A method of determining whether a patient having a hematopoictic malignancy is responding or responsive to anti-cancer agents, comprising:

• measuring a first level GP88 in a tissue sample containing hematopoictic cells obtained from said patient at a first time;
• measuring the level of GP88 in a tissue sample containing hematopoietic cells obtained from said patient at a second time;
• comparing said first level of GP88 with said second level of GP88;
• and
• determining that a patient is not responding or responsive to anti-cancer agents if the second level of GP88 is higher than the first level of GP88.

A method of treating hematopoietic malignancies with an anti-cancer agent in a patient comprising:

• determining a first level of GP88 present in a tissue sample containing hematopoietic cells obtained from said patient at a first time;
• determining a second level of GP88 present in a tissue sample containing hematopoietic cells obtained from said patient at a second time;
• comparing the first level of GP88 with the second level of GP88;
• and
• administering an anti-cancer agent to said patient in an amount sufficient to treat or prevent hemapoietic malignancies if the second level of GP88 is the same as or lower than the first level of GP88.

A method of determining whether a patient is responding or responsive to the anti-tumorigenic effects of anti-cancer therapy comprising:

• determining a first level of GP88 in hematopoeitic cells obtained from said patient at a first time;
• determining a second level of GP88 in hematopoeitic cells obtained from said patient at a second time;
• comparing said first level of GP88 with said second level of GP88;
• and
• determining that a patient is resistant to the anti-tumorigenic effects of anti-cancer therapy if the second level of GP88 is higher than the first level of GP88.

A method of determining whether a patient is responding or responsive to the anti-tumorigenic effects of glucocorticoids or glucocorticoid analogs comprising:

• determining a first level of GP88 in a tissue sample containing B-cells obtained from said patient at a first time;
• determining a second level of GP88 in a tissue sample containing B-cells obtained from said patient at a second time;
• comparing the first level of GP88 with the second level of GP88;
• and
• determining that a patient is resistant to the anti-tumorigenic effects of glucocorticoids if the second level of GP88 is higher that the first level of GP88.